General Information of Drug (ID: DM58UO9)

Drug Name
PMID25991433-Compound-L2 Drug Info
Cross-matching ID
TTD Drug ID
DM58UO9

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Patented Agent(s)
Clinical Trial Drug(s)
Approved Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
PMID25991433-Compound-L3 DM3LWUR N. A. N. A. Patented [1]
PMID25991433-Compound-L1 DM2135Y N. A. N. A. Patented [1]
PMID25991433-Compound-N3 DMLHC5V N. A. N. A. Patented [1]
Drug Name Drug ID Indication ICD 11 Highest Status REF
GBL-310 DM2IFJQ Keratosis ED56 Phase 2 [2]
LTT462 DM94E6W Solid tumour/cancer 2A00-2F9Z Phase 1 [3]
PF-07799544 DMAO10K Aggressive cancer 2A00-2F9Z Phase 1 [4]
PMID25991433-Compound-L3 DM3LWUR N. A. N. A. Patented [1]
Bidentate ligands of Markush derivative 2 DM2QNMC N. A. N. A. Patented [5]
Bidentate ligands of Markush derivative 1 DMB08D3 N. A. N. A. Patented [5]
PMID25991433-Compound-Q1 DMEMSB2 N. A. N. A. Patented [1]
PMID25991433-Compound-C3 DMSKWBE N. A. N. A. Patented [1]
PMID25991433-Compound-J6 DMOWULJ N. A. N. A. Patented [1]
PMID25991433-Compound-L DM5U8WT N. A. N. A. Patented [1]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ozagrel DMIGKA1 Xerophthalmia 5B55.Y Phase 4 [6]
Losmapimod DMIL37Z Acute coronary syndrome BA41 Phase 3 [6]
VX-702 DMKJDR6 Coronary artery disease BA80 Phase 2a [7]
VX-745 DMJAEG6 Alzheimer disease 8A20 Phase 2 [8]
Dilmapimod DMBYJ92 Acute lung injury NB32.3 Phase 2 [6]
PMID25991433-Compound-A1 DM89LF0 N. A. N. A. Patented [1]
PMID25991433-Compound-F2 DM37VIQ N. A. N. A. Patented [1]
PMID25991433-Compound-L3 DM3LWUR N. A. N. A. Patented [1]
PMID25991433-Compound-L1 DM2135Y N. A. N. A. Patented [1]
PMID25991433-Compound-O2 DMTROIQ N. A. N. A. Patented [1]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
JNK-interacting protein peptide (pepJIP) TT3ZIJL NOUNIPROTAC Inhibitor [1]
Mitogen-activated protein kinase (MAPK) TTVOE6D NOUNIPROTAC Inhibitor [1]
Stress-activated protein kinase 2a (p38 alpha) TTQBR95 MK14_HUMAN Inhibitor [1]

References

1 c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
2 WO patent application no. 2010,0456,51, Methods for analyzing drug response.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2023. Adis Insight
5 Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676.
6 Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
7 Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies. Arthritis Rheum. 2009 May;60(5):1232-41.
8 Pharmacological inhibitors of MAPK pathways. Trends Pharmacol Sci. 2002 Jan;23(1):40-5.